Transient receptor potential vanilloid type-1 (TRPV-1) channels contribute to cutaneous thermal hyperaemia in humans.
The initial, rapid increase in skin blood flow in response to direct application of heat is thought to be mediated by an axon reflex, which is dependent on intact cutaneous sensory nerves. We tested the hypothesis that inhibition of transient receptor potential vanilloid type 1 (TRPV-1) channels, which are putative channels located on sensory nerves, would attenuate the skin blood flow response to local heating in humans. Ten subjects were equipped with four microdialysis fibres which were randomly assigned one of four treatments: (1) vehicle control (90% propylene glycol + 10% lactated Ringer solution); (2) 20 mm capsazepine to inhibit TRPV-1 channels; (3) 10 mm l-NAME to inhibit NO synthase; and (4) combined 20 mm capsazepine + 10 mm l-NAME. Following baseline measurements, the temperature of skin heaters was increased from 33°C to 42°C at a rate of 1.0°C every 10 s and local temperature was held at 42°C for 20-30 min until a stable plateau in skin blood flow was achieved. An index of skin blood flow was measured directly over each microdialysis site via laser-Doppler flowmetry (LDF). Beat-by-beat blood pressure was measured via photoplethysmography and verified via automated brachial auscultation. At the end of the local heating protocol, temperature of the heaters was increased to 43°C and 28 mm nitroprusside was infused to achieve maximal vasodilatation. Cutaneous vascular conductance (CVC) was calculated as LDF/mean arterial pressure and normalized to maximal values (%CVCmax). Initial peak in capsazepine (44 ± 4%CVCmax), l-NAME (56 ± 4%CVCmax) and capsazepine + l-NAME (32 ± 6%CVCmax) sites was significantly attenuated compared to control (87 ± 5%CVCmax; P < 0.001 for all conditions). The plateau phase of thermal hyperaemia was significantly attenuated in capsazepine (73 ± 6%CVCmax), l-NAME (47 ± 5%CVCmax) and capsazepine + l-NAME (31 ± 7%CVCmax) sites compared to control (92 ± 5%CVCmax; P < 0.001 for all conditions). These data suggest TRPV-1 channels contribute substantially to the initial peak and modestly to the plateau phases of thermal hyperaemia. These data further suggest a portion of the NO component of thermal hyperaemia may be due to activation of TRPV-1 channels.
Wong
Brett J
BJ
Department of Kinesiology, Kansas State University, Manhattan, KS 66506, USA. bwong@k-state.edu
Fieger
Sarah M
SM
D000328:Adult; D002211:Capsaicin / Q000031:analogs & derivatives / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006358:Hot Temperature; D006801:Humans; D006940:Hyperemia / Q000503:physiopathology*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D012039:Regional Blood Flow / Q000502:physiology; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000502:physiology; D012867:Skin / Q000098:blood supply / Q000294:innervation / Q000503:physiopathology*; D012881:Skin Temperature / Q000502:physiology; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*
D004791:Enzyme Inhibitors; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; C071423:capsazepine; D002211:Capsaicin; D019331:NG-Nitroarginine Methyl Ester
Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R596-602
16484440
Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H232-6
11748067
Mol Pharmacol. 2009 Jun;75(6):1262-79
19297520
J Appl Physiol (1985). 2009 Apr;106(4):1112-8
19196910
J Appl Physiol (1985). 1999 Apr;86(4):1185-90
10194201
Br J Pharmacol. 2005 Sep;146(2):171-9
15997233
Neurosci Lett. 1997 Jul 18;230(2):117-20
9259478
Biochem Pharmacol. 2003 Apr 1;65(7):1035-41
12663039
Mol Pain. 2007 Oct 25;3:30
17961222
Acta Derm Venereol. 1987;67(3):185-92
2442929
Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H123-9
18469149
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2161-7
17660395
Brain Res. 2007 Jul 2;1156:80-92
17540346
PLoS One. 2009 Oct 29;4(10):e7596
19893614
J Appl Physiol (1985). 2003 Aug;95(2):504-10
12692141
J Physiol. 2008 Feb 1;586(3):847-57
18048451
J Appl Physiol (1985). 2008 Jul;105(1):233-40
18483164
J Neurosci. 2003 Jul 9;23(14):6058-62
12853424
Exp Physiol. 2010 Sep;95(9):946-54
20562295
Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R64-76
16973931
J Physiol. 2004 Nov 1;560(Pt 3):941-8
15375193
J Appl Physiol (1985). 2006 Feb;100(2):535-40
16195389
Auton Autacoid Pharmacol. 2009 Jul;29(3):63-72
19566746
J Appl Physiol (1985). 2001 Oct;91(4):1619-26
11568143
Nature. 1997 Oct 23;389(6653):816-24
9349813
Circ Res. 2005 Oct 28;97(9):853-63
16254217
J Neurosci. 2007 Oct 31;27(44):12067-77
17978048
J Physiol. 2005 Mar 15;563(Pt 3):965-73
15661816
Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H51-6
19011042
J Physiol. 1996 Dec 15;497 ( Pt 3):837-48
9003568
J Physiol. 2006 May 1;572(Pt 3):811-20
16497714
Nat Chem Biol. 2006 Nov;2(11):596-607
16998480
Pharmacol Ther. 2006 Jun;110(3):433-54
16226312